Dr. Dosoretz studies the effects of treatments for prostate cancer, comparing surgical options like radical prostatectomy (removal of the prostate) to radiation and hormone therapies. He examines how these interventions impact survival rates, especially in patients who are also managing heart disease. His research is particularly relevant to men experiencing high-risk prostate cancer, helping to clarify which treatment approaches are most effective based on individual health conditions and tumor characteristics. He also explores the interactions between heart health and cancer therapies, aiming to improve overall outcomes for patients.
Key findings
Men with low-risk prostate cancer using neoadjuvant hormone therapy had a 27% higher risk of dying from any cause compared to those who didn't use it.
In a study of nearly 1,342 men with high-risk prostate cancer, those receiving brachytherapy plus both androgen suppression and external-beam radiation had a 68% lower risk of dying from prostate cancer.
Men undergoing coronary artery revascularization had a 37% lower risk of death from prostate cancer compared to those who did not have these procedures.
For healthy elderly men with high-risk prostate cancer, those receiving combined treatments experienced only a 4% mortality rate from prostate cancer, in contrast to higher rates for other treatment groups.
Total androgen blockade reduced the risk of dying from prostate cancer by 82% for men compared to those receiving an LHRH agonist alone.
Frequently asked questions
Does Dr. Dosoretz study prostate cancer?
Yes, Dr. Dosoretz specializes in prostate cancer, focusing on treatment effectiveness and patient health factors.
What treatments has Dr. Dosoretz researched?
He has researched various treatments including radical prostatectomy, radiation therapy, hormone therapy, and their combinations for prostate cancer.
Is Dr. Dosoretz's work relevant to men with heart disease?
Yes, his studies explore how heart disease impacts prostate cancer outcomes and treatment effectiveness.
What are the benefits of his research for prostate cancer patients?
His work helps guide treatment decisions, offering insights on the best approaches for various risk levels and health backgrounds.
Can his findings help elderly men with prostate cancer?
Absolutely, his research provides valuable information on the risks and benefits of different treatments specifically for older men.
Publications in plain English
Neoadjuvant hormonal therapy use and the risk of death in men with prostate cancer treated with brachytherapy who have no or at least a single risk factor for coronary artery disease.
2014
European urology
Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D +4 more
Plain English This study looked at how neoadjuvant hormone therapy (NHT) affects the risk of death in men with prostate cancer who are treated with a specific type of radiation therapy (brachytherapy) and have low or some risk factors for heart disease. It found that men with low-risk prostate cancer who used NHT had a 27% higher risk of dying from any cause compared to those who didn't use it, especially if they had at least one risk factor for heart disease. This is important because it shows that NHT may not be safe for all prostate cancer patients, especially those with low-risk cancer and heart disease risk factors.
Who this helps: This helps patients with prostate cancer and their doctors by informing treatment decisions.
Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
2012
BJU international
Westover K, Chen MH, Moul J, Robertson C, Polascik T +4 more
Plain English This study compared two treatment options for men with high-risk prostate cancer: radical prostatectomy (RP), which is surgery to remove the prostate, and combined-modality therapy (CMT), which includes radiation and hormone therapy. Over an average follow-up of about 4.6 years, 21 men died from prostate cancer, but the study found that the risk of death from cancer was similar for both treatments, with no significant difference. Specifically, factors like a low PSA level (less than 4 ng/mL) were linked to a much higher risk of death, highlighting the importance of these indicators in assessing patient risk.
Who this helps: This information benefits patients with high-risk prostate cancer and their doctors in making treatment decisions.
Coronary artery revascularization and the risk of death in men with prostate cancer.
2011
The Journal of urology
D'Amico AV, Chen MH, Dosoretz D, Katin M, Salenius S +2 more
Plain English This study looked at the relationship between heart procedures (coronary artery revascularization) and the risk of dying from prostate cancer in men who also have heart disease. Researchers found that men who had these heart procedures had a significantly lower risk of death (about 37% less) compared to those who did not have the procedures, despite having other serious health issues. Understanding this relationship is important because it suggests that treating heart disease can improve outcomes for men with prostate cancer.
Who this helps: This helps men with prostate cancer and heart disease, as well as their doctors in making treatment decisions.
Total androgen blockade versus a luteinizing hormone-releasing hormone agonist alone in men with high-risk prostate cancer treated with radiotherapy.
2010
International journal of radiation oncology, biology, physics
Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D +4 more
Plain English This study examined whether a combination treatment of total androgen blockade, which includes an LHRH agonist and an antiandrogen, is more effective than using an LHRH agonist alone in men with high-risk prostate cancer who received radiotherapy. Researchers followed 628 men for nearly 5 years and found that those on the combination therapy had an 82% lower risk of dying from prostate cancer compared to those on monotherapy. The results indicate that using both treatments together can significantly improve outcomes for these patients.
Who this helps: This helps patients with high-risk prostate cancer.
Predictors of prostate cancer-specific mortality in elderly men with intermediate-risk prostate cancer treated with brachytherapy with or without external beam radiation therapy.
2010
International journal of radiation oncology, biology, physics
Nanda A, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D +4 more
Plain English This study looked at elderly men with intermediate-risk prostate cancer to see what factors might predict death from the disease. Researchers found that men with heart disease had a significantly lower chance of dying from prostate cancer, with a risk reduction of 80% (meaning their chance of mortality was 0.20 times lower compared to those without heart disease). Additionally, higher prostate-specific antigen (PSA) levels were linked to an increased risk of death from prostate cancer.
Who this helps: This information is useful for doctors treating elderly patients with prostate cancer, helping them assess risks based on heart health and PSA levels.
Prostate cancer-specific mortality and the extent of therapy in healthy elderly men with high-risk prostate cancer.
2010
Cancer
Hoffman KE, Chen MH, Moran BJ, Braccioforte MH, Dosoretz D +4 more
Plain English This study looked at how different treatments affect the risk of dying from prostate cancer in healthy older men with high-risk prostate cancer. Researchers followed 764 men aged 65 and older, comparing those who received brachytherapy alone to those who got a combination of treatments, including brachytherapy, external radiation, and hormone therapy. They found that men who received the combined treatments had a significantly lower risk of dying from prostate cancer—only about 4% died from it, compared to higher risks for other treatment groups—showing that more aggressive treatment can be beneficial.
Who this helps: This research benefits elderly men with high-risk prostate cancer and their doctors by guiding treatment decisions.
Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease.
2009
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
D'Amico AV, Moran BJ, Braccioforte MH, Dosoretz D, Salenius S +3 more
Plain English The study looked at how different treatments influence the risk of dying from prostate cancer in men with a high risk of the disease. Researchers followed 1,342 men and found that those who received brachytherapy along with both androgen suppression therapy and external-beam radiation therapy had about a 68% lower risk of dying from prostate cancer compared to those who received no supplemental treatments. This matters because it provides important information on which treatment combinations are most effective for improving survival rates in high-risk prostate cancer patients.
Who this helps: This helps men diagnosed with high-risk prostate cancer and their doctors in making informed treatment decisions.
Pentobarbital anesthesia and the response of tumor and normal tissue in the C3Hf/sed mouse to radiation.
1985
Radiation research
Suit HD, Sedlacek RS, Silver G, Dosoretz D
Plain English This study looked at how pentobarbital anesthesia affects the response of tumors and healthy tissue to radiation in mice with different types of cancer. The researchers found that the tumors responded better to radiation when the mice were under the influence of pentobarbital, with effectiveness ratios (ER) going as high as 2.21 for a specific tumor type. This matters because understanding how anesthesia impacts treatment effectiveness can help improve radiation therapy outcomes for cancer patients.
Who this helps: This helps cancer patients by potentially improving the effectiveness of their radiation treatments.
Serum luteinizing hormone follicle-stimulating hormone and prolactin in neonatal-androgenized rats.
1976
Reproduccion
Moguilevsky JA, Scacchi P, Dosoretz D, Rubinstein L
Plain English This study looked at the hormone levels in male and female rats that were treated with testosterone shortly after birth. Researchers found that male rats had higher levels of FSH (follicle-stimulating hormone) and prolactin, while their LH (luteinizing hormone) and testosterone levels did not change. Female rats also showed increased FSH levels after testosterone treatment, but these levels were still lower than those in the males. These findings suggest that exposure to androgens right after birth plays a key role in hormone regulation.
Who this helps: This helps researchers studying hormonal development and its effects on gender differences.
Effects of castration, and testosterone in vitro, on the hypothalamic synthesis of different peptide fractions.
1975
The Journal of endocrinology
Moguilevsky JA, Enero MA, Szwarcfarb B, Dosoretz D
Plain English This study looked at how removing the testicles (castration) affects the production of certain brain peptides in rats, particularly those that help release hormones important for reproduction. The researchers found that after castration, there was a significant increase in the production of small peptides linked to hormone release, specifically in the hormone luteinizing hormone-releasing factor (LH-RF). When testosterone was added back, it reversed some of these changes, suggesting that testosterone plays a key role in regulating these brain peptides.
Who this helps: This information benefits doctors and researchers working on hormonal therapies for reproductive health.